FI110692B - DNA kodande människo-5-HT1D receptorer och användningen - Google Patents
DNA kodande människo-5-HT1D receptorer och användningen Download PDFInfo
- Publication number
- FI110692B FI110692B FI925034A FI925034A FI110692B FI 110692 B FI110692 B FI 110692B FI 925034 A FI925034 A FI 925034A FI 925034 A FI925034 A FI 925034A FI 110692 B FI110692 B FI 110692B
- Authority
- FI
- Finland
- Prior art keywords
- receptor
- human
- ht1d
- cell
- chemical compound
- Prior art date
Links
- 101000724739 Homo sapiens 5-hydroxytryptamine receptor 1D Proteins 0.000 title claims abstract description 157
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 88
- 230000027455 binding Effects 0.000 claims abstract description 70
- 230000014509 gene expression Effects 0.000 claims abstract description 57
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 239000003446 ligand Substances 0.000 claims abstract description 42
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 41
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 38
- 239000013598 vector Substances 0.000 claims abstract description 26
- 108020003175 receptors Proteins 0.000 claims description 193
- 102000005962 receptors Human genes 0.000 claims description 191
- 210000004027 cell Anatomy 0.000 claims description 137
- 108020004414 DNA Proteins 0.000 claims description 105
- 241000282414 Homo sapiens Species 0.000 claims description 100
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 claims description 98
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 78
- 239000013612 plasmid Substances 0.000 claims description 37
- 239000002299 complementary DNA Substances 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 20
- 102000053602 DNA Human genes 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 210000005253 yeast cell Anatomy 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 102000030621 adenylate cyclase Human genes 0.000 claims description 7
- 108060000200 adenylate cyclase Proteins 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 230000009870 specific binding Effects 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- 229940000406 drug candidate Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims 7
- 101000783609 Homo sapiens 5-hydroxytryptamine receptor 1E Proteins 0.000 claims 1
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000009137 competitive binding Effects 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 abstract description 31
- 241001465754 Metazoa Species 0.000 abstract description 21
- 230000000295 complement effect Effects 0.000 abstract description 16
- 239000000074 antisense oligonucleotide Substances 0.000 abstract description 12
- 238000012230 antisense oligonucleotides Methods 0.000 abstract description 12
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract description 8
- 239000002853 nucleic acid probe Substances 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract description 2
- 238000007877 drug screening Methods 0.000 abstract 1
- 102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 description 45
- 108020004999 messenger RNA Proteins 0.000 description 45
- 239000003814 drug Substances 0.000 description 41
- 229940079593 drug Drugs 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 34
- 108091026890 Coding region Proteins 0.000 description 32
- 101100321769 Takifugu rubripes htr1d gene Proteins 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 241000282465 Canis Species 0.000 description 19
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- 230000000144 pharmacologic effect Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000013519 translation Methods 0.000 description 15
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 14
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000005856 abnormality Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000002018 overexpression Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000001766 physiological effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 102000035038 5-HT1 receptors Human genes 0.000 description 6
- 108091005478 5-HT1 receptors Proteins 0.000 description 6
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 206010027599 migraine Diseases 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 5
- 108091005479 5-HT2 receptors Proteins 0.000 description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- 102000030782 GTP binding Human genes 0.000 description 5
- 108091000058 GTP-Binding Proteins 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 108010010573 serotonin 1C receptor Proteins 0.000 description 5
- 230000009452 underexpressoin Effects 0.000 description 5
- WKZLNEWVIAGNAW-UHFFFAOYSA-N 5-Carboxyamidotryptamine Chemical compound C1=C(C(N)=O)C=C2C(CCN)=CNC2=C1 WKZLNEWVIAGNAW-UHFFFAOYSA-N 0.000 description 4
- 108020004491 Antisense DNA Proteins 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 101150050738 HTR1B gene Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000003816 antisense DNA Substances 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 229960003708 sumatriptan Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- GOTMKOSCLKVOGG-OAHLLOKOSA-N (5R)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 GOTMKOSCLKVOGG-OAHLLOKOSA-N 0.000 description 3
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 101150015707 HTR1A gene Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 241000894007 species Species 0.000 description 3
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- -1 amino- Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 230000020595 eating behavior Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
- 229960005417 ketanserin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 210000003370 receptor cell Anatomy 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000004001 serotonin 1D antagonist Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- HEAUFJZALFKPBA-JPQUDPSNSA-N (3s)-3-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-JPQUDPSNSA-N 0.000 description 1
- JZQKKSLKJUAGIC-NSHDSACASA-N (S)-(-)-pindolol Chemical compound CC(C)NC[C@H](O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-NSHDSACASA-N 0.000 description 1
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- ZNRGQMMCGHDTEI-UHFFFAOYSA-N 1H-indole-3-carboxylic acid (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) ester Chemical compound C1=CC=C2C(C(=O)OC3CC4CCC(C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-UHFFFAOYSA-N 0.000 description 1
- 108091071337 20 family Proteins 0.000 description 1
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 description 1
- 101710138085 5-hydroxytryptamine receptor 1E Proteins 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000289427 Didelphidae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150004776 HTR1E gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010024777 Mating Factor Receptors Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- 101800000399 Neurokinin A Proteins 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 101150089730 gly-10 gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229950002454 lysergide Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229950008693 mesulergine Drugs 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000003346 radioligand binding method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229940080360 rauwolfia alkaloid Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- SWERVVWWNZOXPV-UHFFFAOYSA-N samanine Chemical compound C1CC2CCNCCC2(C)C2C1C1CC(O)CC1(C)CC2 SWERVVWWNZOXPV-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004000 serotonin 1B antagonist Substances 0.000 description 1
- 108010030336 serotonin 1E receptor Proteins 0.000 description 1
- 108010053303 serotonin 1F receptor Proteins 0.000 description 1
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/82—Subcellular parts of microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (28)
1. Isolerad nukleinsyramolekyl, kännetecknad av att den kodar för en human 5-HT1D-receptor, där receptorn har en aminosyrasekvens kodad av DNA-sekvensen som finns närvaran-de i plasmid pcEXV-8-30-84 (ATCC-nr. 40790) eller plasmid 10 pSVL-11 (ATCC-nr. 40791), eller en del därav, som har samma bindningsegenskaper som den humana 5-HT1D-receptorn visad i Tabell 1.
2. Isolerad nukleinsyramolekyl, kännetecknad av att den är en degenererad molekyl med avseende pä nukleinsyramolekylen 15 enligt patentkrav 1.
3. Isolerad nukleinsyramolekyl, kännetecknad av att den har en homologi av ätminstone 65 % med en nukleinsyramole- ;·,· kyl enligt patentkrav 1 eller 2 och som kodar för ett pro- ,··· tein vilket har väsentligen samma bindningsegenskaper. 2 0
4. Nukleinsyramolekyl enligt patentkrav 1, 2 eller 3, kän- ·/· netecknad av att nukleinsyramolekylen är en DNA-molekyl, en cDNA-molekyl eller en RNA-molekyl.
5-HT.r-receptorn, varvid en minskning i bindningen av den andra kemiska föreningen tili den humana 5-HT .- receptorn i 5 närvaro av den kemiska föreningen är en indikation pä att den kemiska föreningen binds till den humana 5-Hlh-recep-torn.
5-HT1D-receptor, eller en membran fraktion frän ett cell-extrakt därav, i kontakt med liganden under betingelser som möjliggör bindning av ligander, vilka är kända för att binda tili en 5-HT1D-receptor, detekterar närvaro av eventuella 2 5 ligander som har bundits tili den humana 5-HTlc-receptorn och därigenom bestämmer huruvida liganden binder till en * ,, human 5-HT,D-receptor.
5. Vektor, kännetecknad av att den innefattar en nukleinsyramolekyl enligt vilket som heist av patentkraven 1-4. '•,25
6. Vektor enligt patentkrav 5, kännetecknad av att nämnda nukleinsyramolekyl föreligger under kontroll av reglerande • · element som möjliggör expression i en önskad värdcell.
7. Plasmid, kännetecknad av att den innefattar en vektor ’ enligt patentkrav 5 eller 6. ,30
8. Plasmid enligt patentkrav 7, kännetecknad av att den är plasmid pcEXV-8-30-84 (ATCC-nr. 40790). 61 110692
9. Plasmid enligt patentkrav 7, kannetecknad av att den är plasmid pSVL-11 (ATCC-nr. 40791).
10. Värdcell, kännetecknad av att den innehäller en plasmid enligt vilket som heist av patentkraven 7-9. 5
11. Värdcell enligt patentkrav 10, kännetecknad av att den är en bakteriecell, en jästcell eller en däggdjurscell.
12. Värdcell enligt patentkrav 11, kännetecknad av att den är en Ltk-cell.
13. Värdcell enligt patentkrav 12, kännetecknad av att den 10 innefattar plasmiden enligt patentkrav 8 betecknad Ltk-8- 30-84 (ATCC-nr. CRL 10421).
14. Värdcell enligt patentkrav 12, kännetecknad av att den innefattar plasmiden enligt patentkrav 9 betecknad Ltk-11 (ATCC-nr. CRL 10422).
15 15. Förfarande för bestämning av huruvida en ligand, som , inte är känd för att kunna binda tili en human 5-HT1D- ··; receptor kodad av nukleinsyramolekylen enligt patentkrav 1, kan binda tili en human 5-HT1D-receptor, kännetecknat av att det innefattar att man bringar en däggdjurscell transfekte- • 20 rad med, och uttryckande, nukleinsyra kodande för en human
16. Förfarande för screening av kemiska föreningar för iden-tifiering av läkemedelskandidater, vilka specifikt binder . . 30 till en human 5-HT1D-receptor kodad av en nukleinsyramolekyl enligt patentkrav 1 pä ytan av en cell, kännetecknat av att det innefattar att man bringar en däggdjurscell transfekte-rad med, och uttryckande, nukleinsyra kodande för den hu- 62 110692 mana 5-HTir-receptorn, eller en membranf raktion frän ett cellextrakt därav, i kontakt med en serie kemiska förening-ar, bestämmer vilka kemiska föreningar som binder till den humana 5-HT.„-receptorn som uttryckes pä ytan av däggdjurs-5 cellen och därigenom identifierar läkemedelskandidater, vil ka specifikt binder till en human 5-HT1D-receptor.
17. Membranpreparat, kännetecknat av att det innefattar en human 5-HT1D-receptor isolerad frän en cell enligt vilket som heist av patentkraven 10-14. 10
18. Förfarande enligt patentkrav 15 eller 16, kännetecknat av att däggdjurscellen inte är av nervcellsursprung.
19. Förfarande enligt patentkrav 18, kännetecknat av att däggdjurscellen, som inte är av nervcellsursprung, är en Ltk-cell. 15
20. Förfarande för identifiering av en kemisk förening, vilken specifikt binder till en human 5-HT1D-receptor kodad av en nukleinsyramolekyl enligt patentkrav 4, kännetecknat • av att det innefattar att man bringar celler, som inte är nervceller, vilka pä sin cellyta uttrycker den humana 5-’•20 HT1D-receptorn, eller en membranfraktion frän ett cellext rakt därav, i kontakt med den kemiska föreningen under be-, tingelser som är lämpliga för bindning och detekterar spe- cifik bindning av den kemiska föreningen tili den humana 5-HT1D-receptorn. 25
21. Förfarande som innefattar kompetitiv bindning för iden- tifiering av en kemisk förening som specifikt binder till '·, en human 5-HT1D-receptor kodad av en nukleinsyramolekyl en ligt patentkrav 4, kännetecknat av att det innefattar att ' man separat bringar celler, som inte är nervceller, vilka • ‘ 30 pä sin cellyta uttrycker en human 5-HT1D-receptor, eller en membranfraktion av ett cellextrakt därav, i kontakt med bä-de den kemiska föreningen och en andra kemisk förening, vilken är känd för att binda tili receptorn, och med enbart den andra kemiska föreningen, under betingelser som är 63 110692 lämpliga för bindning av bäda föreningarna och detekterar specifik bindning av den kemiska föreningen tili den humana
22. Förfarande för bestämning av huruvida en kemisk före-ning specifikt binder till, och aktiverar, en human 5-HT1D-10 receptor kodad av en nukleinsyramolekyl enligt patentkrav 4, kannetecknat av att det innefattar att man bringar cel-ler, som inte är nervceller, vilka producerar en andra bud-bärarrespons och pä sin cellyta uttrycker en human 5-HTlp-receptor, eller en membranfraktion av ett cellextrakt där-15 av, i kontakt med den kemiska föreningen under betingelser som är lämpliga för aktivering av den humana 5-HT.,-receptorn och uppmäter den andra budbärarresponsen i närvaro och i avsaknad av den kemiska föreningen, varvid en förändring i andra budbärarrespons i närvaro av den kemiska föreningen 2 0 är en indikation pä att den kemiska föreningen aktiverar •« · | ’t den humana 5-HT1E-receptorn.
► ”! 23. Förfarande för bestämning av huruvida en kemisk före- i *' ning specifikt binder till, och inhiberar aktivering av, ; ‘ human 5-HT1D-receptor kodad av en nukleinsyramolekyl enligt ·' 2 5 patentkrav 4, kännetecknat av att det innef attar att man bringar celler, som inte är nervceller, vilka producerar en andra budbärarrespons och pä sin cellyta uttrycker en human 5-HT1D-receptor, eller en membranf raktion av ett cellextrakt därav, i kontakt med bäde den kemiska föreningen och en ' 30 andra kemisk förening, vilken är känd för att aktivera den ’ humana 5-HT:c-receptorn, och med enbart den andra kemiska föreningen under betingelser som är lämpliga för aktivering av den humana 5-HT!D-receptorn och uppmäter den andra budbärarresponsen i närvaro av enbart den andra kemiska förenin-' 35 gen och i närvaro av bäde den andra kemiska föreningen och den kemiska föreningen, varvid en mindre förändring i andra 64 budbärarrespons i närvaro av bade den kemiska föreningen och den andra kemiska föreningen än i närvaro av enbart den andra kemiska föreningen är en indikation pä att den kemiska föreningen inhiberar aktivering av den humana 5-HT,„-5 receptorn.
24. Förfarande enligt krav 22, kännetecknat av att den andra budbärarresponsen innefattar adenylatcyklasaktivitet och förändringen i andra budbärarrespons är minskning i adenylatcyklasaktivitet . 10
25. Förfarande enligt patentkrav 23, kännetecknat av att den andra budbärarresponsen innefattar adenylatcyklasaktivitet och förändringen i andra budbärarrespons är en mindre minskning i nivan av adenylatcyklasaktivitet i närvaro av bade den kemiska föreningen och den andra kemiska före-15 ningen än i närvaro av endast den andra kemiska föreningen.
26. Förfarande enligt vilket som heist av patentkraven 2 0- 25, kännetecknat av att cellen som inte är en nervcell är en däggdjurscell. * * K
» · * • 27. Förfarande enligt patentkrav 26, kännetecknat av att : 20 däggdjurscellen är en Ltk-cell.
28. Renad human 5-HT1D-receptorprotein med aminosyrasekvens-sen enligt patentkrav 1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52071690 | 1990-05-08 | ||
| US07/520,716 US5155218A (en) | 1990-05-08 | 1990-05-08 | Dna encoding human 5-ht1d receptors |
| US9103200 | 1991-05-08 | ||
| PCT/US1991/003200 WO1991017174A1 (en) | 1990-05-08 | 1991-05-08 | Dna encoding human 5-ht1d receptors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI925034A FI925034A (fi) | 1992-11-06 |
| FI925034A0 FI925034A0 (fi) | 1992-11-06 |
| FI110692B true FI110692B (sv) | 2003-03-14 |
Family
ID=24073787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI925034A FI110692B (sv) | 1990-05-08 | 1992-11-06 | DNA kodande människo-5-HT1D receptorer och användningen |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US5155218A (sv) |
| EP (2) | EP0530265B1 (sv) |
| JP (2) | JP3319596B2 (sv) |
| AT (1) | ATE171211T1 (sv) |
| CA (2) | CA2374571A1 (sv) |
| DE (2) | DE69130219T2 (sv) |
| DK (1) | DK0530265T3 (sv) |
| ES (1) | ES2059298T3 (sv) |
| FI (1) | FI110692B (sv) |
| NO (1) | NO310031B1 (sv) |
| WO (1) | WO1991017174A1 (sv) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661024A (en) | 1989-10-31 | 1997-08-26 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonic (5-HT2) receptor and uses thereof |
| US5935925A (en) * | 1990-05-08 | 1999-08-10 | Synaptic Pharmaceutical Corporation | Methods of treating migraine and compounds useful for such methods |
| US5155218A (en) * | 1990-05-08 | 1992-10-13 | Neurogenetic Corporation | Dna encoding human 5-ht1d receptors |
| AU671417B2 (en) * | 1991-03-15 | 1996-08-29 | Merck Serono Sa | Human follicle stimulating hormone receptor |
| ES2237747T3 (es) * | 1991-11-14 | 2005-08-01 | Prionics Ag | Animales transgenicos no humanos que carecen de proteinas prionicas. |
| DE585415T1 (de) * | 1991-12-02 | 1996-10-10 | Synaptic Pharma Corp | Dns-kodierend für den menschlichen 5-ht 1e rezeptor und seine verwendung. |
| US5670113A (en) | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
| US6406859B1 (en) * | 1992-01-08 | 2002-06-18 | Synaptic Pharmaceutical Corporation | DNA encoding a 5-HT 1F receptor and uses thereof |
| US5360735A (en) * | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
| DE4216319A1 (de) * | 1992-05-16 | 1993-11-18 | Basf Ag | Serotonin Rezeptor, Verfahren zur Herstellung und seine Verwendung |
| FR2693200B1 (fr) * | 1992-07-01 | 1994-08-19 | Inst Nat Sante Rech Med | Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations. |
| FR2693201B1 (fr) * | 1992-07-01 | 1994-08-19 | Inst Nat Sante Rech Med | Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polyptides et utilisations. |
| EP0663014B1 (en) | 1992-09-25 | 2004-08-18 | Synaptic Pharmaceutical Corporation | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| AU5452294A (en) * | 1992-10-26 | 1994-05-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | The st-b17 serotonin receptor |
| ATE279515T1 (de) * | 1992-10-26 | 2004-10-15 | Us Gov Health & Human Serv | Pct-65 serotonin rezeptor |
| EP0624100B1 (en) | 1992-11-03 | 2000-05-03 | Synaptic Pharmaceutical Corporation | Dna encoding a human serotonin receptor (5-ht 4b) and uses thereof |
| US6300087B1 (en) | 1992-11-03 | 2001-10-09 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonin receptor (5-HT4B) and uses thereof |
| US5472866A (en) * | 1992-12-24 | 1995-12-05 | Synaptic Pharmaceutical Corporation | DNA encoding 5-HT4A serotonin receptors |
| FR2699922B1 (fr) * | 1992-12-30 | 1995-02-10 | Inst Nat Sante Rech Med | Polypeptides à activité de récepteur sérotoninergique, médicaments les comprenant, séquences codant pour eux, sondes vecteurs et hôtes les exprimant, et application au criblage des médicaments. |
| US20020115149A1 (en) * | 1993-01-08 | 2002-08-22 | Synaptic Pharmaceutical Corporation | DNA encoding human 5-HT1D receptors and uses thereof |
| US5807711A (en) * | 1993-03-23 | 1998-09-15 | Taisho Pharmaceutical Co., Ltd. | Parenchymal hepatocyte growth factors |
| AU1550195A (en) * | 1994-11-18 | 1996-06-17 | Human Genome Sciences, Inc. | G-protein coupled receptor |
| WO1996030406A1 (en) * | 1995-03-30 | 1996-10-03 | Human Genome Sciences, Inc. | Human g-protein coupled receptors |
| US6090575A (en) * | 1995-03-30 | 2000-07-18 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPR1 |
| US5998164A (en) * | 1995-03-30 | 1999-12-07 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPRZ |
| US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
| US5942414A (en) * | 1995-06-06 | 1999-08-24 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor HIBEF51 |
| AU7434996A (en) * | 1995-10-19 | 1997-05-07 | Smithkline Beecham Corporation | A novel human b cell surface molecule |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| JP2000506365A (ja) * | 1996-01-11 | 2000-05-30 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | ヒトｇタンパク質ケモカインレセプターｈｓａｔｕ６８ |
| CA2242908A1 (en) * | 1996-01-11 | 1997-07-17 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor hsatu68 |
| US6673535B1 (en) | 1996-05-08 | 2004-01-06 | Cedars-Sinai Medical Center | Methods of detecting spinocerebellar Ataxia-2 nucleic acids |
| US6844431B1 (en) * | 1996-05-08 | 2005-01-18 | Cedars-Sinai Medical Center | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| US6462188B1 (en) | 1998-04-16 | 2002-10-08 | The Institute For Genomic Research | Human 5-HT3 receptor |
| WO2000012707A1 (en) * | 1998-09-02 | 2000-03-09 | Millennium Pharmaceuticals, Inc. | 14926 receptor, a novel g-protein coupled receptor |
| US7449338B2 (en) * | 1998-10-02 | 2008-11-11 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| US6664373B1 (en) | 1999-03-01 | 2003-12-16 | Millennium Pharmaceuticals, Inc. | TWIK-5 potassium channel polypeptides and uses therefor |
| US6670149B1 (en) | 1999-03-01 | 2003-12-30 | Millennium Pharmaceuticals, Inc. | TWIK-5 potassium channel nucleic acids and uses therefor |
| US7179886B1 (en) * | 1999-06-08 | 2007-02-20 | Merck & Co., Inc. | Cloning and identification of the motilin receptor |
| JP2003506042A (ja) | 1999-08-03 | 2003-02-18 | ミレニアム ファーマシューティカルズ インク． | セクレチン様ファミリーの新規ｇｐｃｒ様分子１５５７１及びその使用 |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| ES2426915T3 (es) | 2003-09-10 | 2013-10-25 | Brentwood Equities Ltd. | Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas |
| US20070270339A1 (en) * | 2004-04-23 | 2007-11-22 | Serono, Inc. | Use of GPCR54 Ligands for the Treatment of Infertility |
| US20080014172A1 (en) * | 2004-05-28 | 2008-01-17 | Applied Research Systems Ars Holding N.V. | Use of Il-17 in the Treatment of Fertility-Related Disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR79215B (sv) * | 1982-06-07 | 1984-10-22 | Glaxo Group Ltd | |
| WO1985001961A1 (en) | 1983-10-28 | 1985-05-09 | Genetics Institute | Production of factor viii and related products |
| GB2162522B (en) * | 1984-08-01 | 1988-02-24 | Glaxo Group Ltd | An indole derivative |
| GB8419575D0 (en) * | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
| US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
| EP0351921A3 (en) * | 1988-07-22 | 1991-07-17 | Merck & Co. Inc. | Modified beta adrenergic receptor |
| FR2642075B1 (fr) | 1989-01-25 | 1991-04-26 | Pasteur Institut | Polypeptides ayant une activite de recepteur (beta)-adrenergique chez l'homme, impliques dans la reponse lipolytique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substance active sur ces polypeptides |
| US5155218A (en) * | 1990-05-08 | 1992-10-13 | Neurogenetic Corporation | Dna encoding human 5-ht1d receptors |
| DE585415T1 (de) * | 1991-12-02 | 1996-10-10 | Synaptic Pharma Corp | Dns-kodierend für den menschlichen 5-ht 1e rezeptor und seine verwendung. |
| US5360735A (en) * | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
| US5472866A (en) * | 1992-12-24 | 1995-12-05 | Synaptic Pharmaceutical Corporation | DNA encoding 5-HT4A serotonin receptors |
-
1990
- 1990-05-08 US US07/520,716 patent/US5155218A/en not_active Expired - Lifetime
-
1991
- 1991-05-08 AT AT91909881T patent/ATE171211T1/de not_active IP Right Cessation
- 1991-05-08 DK DK91909881T patent/DK0530265T3/da active
- 1991-05-08 DE DE69130219T patent/DE69130219T2/de not_active Expired - Lifetime
- 1991-05-08 CA CA002374571A patent/CA2374571A1/en not_active Abandoned
- 1991-05-08 DE DE91909881T patent/DE530265T1/de active Pending
- 1991-05-08 JP JP50985691A patent/JP3319596B2/ja not_active Expired - Lifetime
- 1991-05-08 CA CA002082390A patent/CA2082390C/en not_active Expired - Lifetime
- 1991-05-08 EP EP91909881A patent/EP0530265B1/en not_active Expired - Lifetime
- 1991-05-08 EP EP96118890A patent/EP0787797A1/en not_active Withdrawn
- 1991-05-08 ES ES91909881T patent/ES2059298T3/es not_active Expired - Lifetime
- 1991-05-08 WO PCT/US1991/003200 patent/WO1991017174A1/en active IP Right Grant
-
1992
- 1992-11-06 NO NO924289A patent/NO310031B1/no not_active IP Right Cessation
- 1992-11-06 FI FI925034A patent/FI110692B/sv active
-
1994
- 1994-05-02 US US08/236,686 patent/US5786157A/en not_active Expired - Lifetime
-
1999
- 1999-08-09 US US09/371,705 patent/US6475746B1/en not_active Expired - Fee Related
-
2001
- 2001-11-21 JP JP2001356183A patent/JP2002212103A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FI925034A (fi) | 1992-11-06 |
| NO924289L (no) | 1992-12-18 |
| EP0787797A1 (en) | 1997-08-06 |
| NO924289D0 (no) | 1992-11-06 |
| JP2002212103A (ja) | 2002-07-31 |
| US5786157A (en) | 1998-07-28 |
| ES2059298T1 (es) | 1994-11-16 |
| DE69130219D1 (de) | 1998-10-22 |
| EP0530265B1 (en) | 1998-09-16 |
| DE530265T1 (de) | 1994-03-31 |
| AU657686B2 (en) | 1995-03-23 |
| ATE171211T1 (de) | 1998-10-15 |
| AU7879891A (en) | 1991-11-27 |
| WO1991017174A1 (en) | 1991-11-14 |
| CA2374571A1 (en) | 1991-11-14 |
| ES2059298T3 (es) | 1999-02-01 |
| JP3319596B2 (ja) | 2002-09-03 |
| US5155218A (en) | 1992-10-13 |
| FI925034A0 (fi) | 1992-11-06 |
| CA2082390C (en) | 2002-06-11 |
| EP0530265A1 (en) | 1993-03-10 |
| DE69130219T2 (de) | 1999-05-12 |
| CA2082390A1 (en) | 1991-11-09 |
| DK0530265T3 (da) | 1999-06-14 |
| EP0530265A4 (en) | 1993-06-16 |
| NO310031B1 (no) | 2001-05-07 |
| US6475746B1 (en) | 2002-11-05 |
| JPH06502297A (ja) | 1994-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI110692B (sv) | DNA kodande människo-5-HT1D receptorer och användningen | |
| US5360735A (en) | DNA encoding a human 5-HT1F receptor, vectors, and host cells | |
| US5472866A (en) | DNA encoding 5-HT4A serotonin receptors | |
| AU672768B2 (en) | DNA encoding a human 5-HT-1E receptor and uses thereof | |
| WO1993010228A1 (en) | Dna encoding a glycine transporter and uses thereof | |
| US6432655B1 (en) | Method of obtaining compositions | |
| US6468767B1 (en) | DNA encoding a human dopamine D1 receptor and uses thereof | |
| US5935925A (en) | Methods of treating migraine and compounds useful for such methods | |
| AU657686C (en) | DNA encoding human 5-HT1D receptors and uses thereof | |
| US6300087B1 (en) | DNA encoding a human serotonin receptor (5-HT4B) and uses thereof | |
| Weinshank et al. | DNA encoding human 5-HT 1D receptors | |
| WO1994015618A1 (en) | Dna encoding a human betaine/gaba transporter and uses thereof | |
| US20020115149A1 (en) | DNA encoding human 5-HT1D receptors and uses thereof | |
| US6406859B1 (en) | DNA encoding a 5-HT 1F receptor and uses thereof | |
| AU667510C (en) | DNA encoding a human 5-HT-1F receptor and uses thereof | |
| Gerald et al. | DNA encoding 5-HT4A serotonin receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: LUNDBECK RESEARCH USA, INC. Free format text: LUNDBECK RESEARCH USA, INC. |